Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.

Scott T Tagawa Krishnan RamaswamyAhong HuangJack MardekianNeil M SchultzLi WangRickard SandinStanislav LechpammerDaniel J George

Published in: Prostate cancer and prostatic diseases (2021)

Retrospective analysis of the VHA database indicated that chemotherapy-naive patients with mCRPC initiating therapy with enzalutamide had improved survival versus abiraterone.

Keyphrases

prostate cancer
locally advanced
hiv infected
squamous cell carcinoma
small cell lung cancer
cross sectional
stem cells
rectal cancer
chemotherapy induced
radiation therapy